Not recruiting yet
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
NCT07418034 · University of Maryland, Baltimore · Updated 14 Aug 2026
- What is being tested
- Dose de-escalation to contralateral neck.; Dose de-escalation to gross disease to contralateral neck; Dose de-escalation to gross disease; Circulating Tumor DNA test (ctDNA test)
- For
- Head and Neck Cancer; Head and Neck Squamous Cell Cancer; Head and Neck Squamous Cell Carcinoma; Oropharyngeal Carcinoma; Oropharyngeal Squamous Cell Carcinoma (OPSCC); Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma (SCC); Oropharyngeal Squamous Cell Carcinoma (OPSCCA); Oropharyngeal Cancer; Oropharyngeal Squamous Cell Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV (Human Papillomavirus)-Associated Carcinoma; HPV 16 Positive Oropharyngeal Tumors (OPC)
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years and older. About 132 people. The full rules are on the registry page.
- Where
- Not stated
- When
- Starts or started Sept 2026, ends May 2033. Registered 18 Feb 2026.
- Results
- None posted yet.
In the researchers' words
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the specific type of treatment they receive. However, the different treatments used for this cancer can cause significant side effects. Because outcomes are often favorable regardless of treatment type, reducing treatment-related side effects should be a priority when choosing care. Studies have reported that lowering radiation doses for some patients can reduce side effects while still effectively controlling the cancer. Patients with this type of head and neck cancer typically receive either surgery or radiation as their first treatment. For patients who receive surgery first, radiation to the surgical area and nearby neck lymph nodes is often recommended afterward. In these patients, the study will test whether lowering the radiation dose to low-risk lymph nodes on the side of the neck opposite the tumor can reduce side effects while still effectively controlling the cancer (Method A). For patients who receive radiation as their first treatment, the study will test one or both of two radiation approaches aimed at reducing both short-term and long-term side effects. These approaches include reduced lymph node radiation (Method A, described above) and…
